BELLUS Health Inc logo

BLU - BELLUS Health Inc News Story

$3.64 0.2  5.5%

Last Trade - 14/05/21

Sector
Healthcare
Size
Small Cap
Market Cap £191.7m
Enterprise Value £133.7m
Revenue £10.7k
Position in Universe 4227th / 6849

BRIEF-Bellus Health Announces First Patient Dosed In Its Phase 2 Blueprint Trial Of Blu-5937

Mon 14th December, 2020 12:02pm
Dec 14 (Reuters) - BELLUS Health Inc  BLU.TO :
    * BELLUS HEALTH ANNOUNCES FIRST PATIENT DOSED IN ITS PHASE 2
BLUEPRINT TRIAL OF BLU-5937 FOR TREATMENT OF CHRONIC PRURITUS
ASSOCIATED WITH ATOPIC DERMATITIS
    * TOPLINE RESULTS FROM PHASE 2 TRIAL EXPECTED IN Q4 2021

Source text for Eikon:  ID:nBw5xnDMQa 
Further company coverage:  BLU.TO 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.